Feature

Video: Reducing Injections in Wet AMD

Avni Finn, MD, and Diana V. Do, MD, discuss promising results from the DAVIO2 trial of EYP-1901.

Share

  • 1

    EYP-1901 is a tyrosine kinase inhibitor for wet macular degeneration.

  • 2

    Patients traditionally need frequent anti-VEGF injections.

  • 3

    DAVIO2 trial showed reduction of injections from 10 to 1-2 yearly.

  • 4

    EYP-1901 offers a longer lasting treatment option (~6 months).

  • 5

    Potential to lower treatment burden and improve compliance.

Original Source(s)

Video: Reducing Injections in Wet AMD

Avni Finn, MD, and Diana V. Do, MD, discuss promising results from the DAVIO2 trial of EYP-1901.

  • by Avni Finn, MD, MBA, Diana V. Do, MD

  • July 14, 2025

  • 2 min

Related Content

EYP-1901 for Retinal Exudative Diseases

An overview of the current status of the EYP-1901 clinical trial program in wet AMD and DME, presented at Hawaiian Eye and Retina 2026

When the Kidney Meets the Retina

New study suggests potential causal link between kidney disease and AMD

  • January 22, 2026

  • 3 min
Coding Q&A: Coding Guidelines for Wet AMD

Proper use of ICD-10-CM codes ensures compliance and prompt payment.